All Stories

  1. Validation of a web-based distance visual acuity test
  2. Impact of Light Conditions on Visual Performance following Premium Pseudophakic Presbyopia Corrections
  3. Changing from preserved, to preservative-free cyclosporine 0.1% enhanced triple glaucoma therapy: impact on ocular surface disease—a randomized controlled trial
  4. Patient-reported burden and overall impact of dry eye disease across eight European countries: a cross-sectional web-based survey
  5. Toxic conjunctivitis due to cosmetics: Description of the pathology and evaluation of topical treatment with unpreserved hydrocortisone 3.35 mg/ ml and ketotifen 0.25 mg/ ml
  6. Emerging Treatment Modalities for Neovascular Age-Related Macular Degeneration: A Systematic Overview
  7. The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy
  8. Hypopyon after Primary Cryopreserved Amniotic Membrane Transplantation for Sterile Corneal Ulceration: A Case Report and Review of the Literature
  9. Letter to the editor: ‘topical preservative-free ophthalmic treatments an unmet clinical need’
  10. The treatment of glaucoma using topical preservative-free agents: an evaluation of safety and tolerability
  11. Correction to: 24-Hour Efficacy and Ocular Surface Health with Preservative-Free Tafluprost Alone and in Conjunction with Preservative-Free Dorzolamide/Timolol Fixed Combination in Open-Angle Glaucoma Patients Insufficiently Controlled with Preserved L...
  12. Response to Comments on Randomized Controlled Trial Comparing Everting Sutures with a Lateral Tarsal Strip for Involutional Lower Eyelid Entropion
  13. Risk factors for local recurrence of basal cell carcinoma and cutaneous squamous cell carcinoma of the middle third of the face: a 15-year retrospective analysis based on a single centre
  14. Meibomian gland inversion: under‐recognized entity
  15. Randomized Controlled Trial Comparing Everting Sutures with a Lateral Tarsal Strip for Involutional Lower Eyelid Entropion
  16. Association between vitamin D receptor gene polymorphisms and Graves’ disease: a systematic review and meta-analysis
  17. Revisiting Ocular Allergy: Evaluating Symptoms, Benzalkonium Chloride and Efficacy of Topical Ketotifen 0.025%
  18. Lack of Association of the rs11655081 ARSG Gene with Blepharospasm
  19. BDNF rs6265 (Val66Met) Polymorphism as a Risk Factor for Blepharospasm
  20. Role of corneal nerves in ocular surface homeostasis and disease
  21. Evaluating the novel application of cyclosporine 0.1% in ocular surface disease
  22. Controlled Adverse Environment Chambers in Dry Eye Research
  23. sight threatening Graves Disease- use of Rituximab
  24. Preservative-Free Prostaglandin Analogs and Prostaglandin/Timolol Fixed Combinations in the Treatment of Glaucoma: Efficacy, Safety and Potential Advantages
  25. Management of very severe Graves' orbitopathy with low dose rituximab: report of two cases
  26. Orbital disease primer for Endocrinologists-not always thyroid associated orbitopathy (TAO): a case vignette
  27. Graves’ orbitopathy as a rare disease in Europe: a European Group on Graves’ Orbitopathy (EUGOGO) position statement
  28. Emerging strategies for the diagnosis and treatment of meibomian gland dysfunction: Proceedings of the OCEAN group meeting
  29. Visual acuity and quality of life in dry eye disease: Proceedings of the OCEAN group meeting
  30. Does early response to intravenous glucocorticoids predict the final outcome in patients with moderate-to-severe and active Graves’ orbitopathy?
  31. Local Treatment Modalities
  32. 24-Hour Efficacy and Ocular Surface Health with Preservative-Free Tafluprost Alone and in Conjunction with Preservative-Free Dorzolamide/Timolol Fixed Combination in Open-Angle Glaucoma Patients Insufficiently Controlled with Preserved Latanoprost Mono...
  33. Natural course of mild Graves’ orbitopathy: is it a chronic remitting or a transient disease?
  34. Revisiting the vicious circle of dry eye disease: a focus on the pathophysiology of meibomian gland dysfunction
  35. Critical Appraisal on Orbital Decompression for Thyroid Eye Disease: A Systematic Review and Literature Search
  36. 24-Hour Efficacy of Travoprost/Timolol BAK-Free Versus Latanoprost/Timolol Fixed Combinations in Patients Insufficiently Controlled with Latanoprost
  37. New Perspectives on Lamellar Keratoplasty
  38. Refractory Graves' ophthalmopathy treated with rituximab
  39. Role of Hyperosmolarity in the Pathogenesis and Management of Dry Eye Disease: Proceedings of the OCEAN Group Meeting
  40. B-Cell Targeted Therapy With Rituximab for Thyroid Eye Disease: Closer to the Clinic
  41. Corneal Transplant Infection due toAlternaria alternata: A Case Report
  42. Efficacy and Safety of Three Different Cumulative Doses of Intravenous Methylprednisolone for Moderate to Severe and Active Graves' Orbitopathy
  43. Descemet's Stripping Endothelial Automated Keratoplasty Using Tan Endoglide Endothelium Insertion System
  44. Surgical orbital decompression for thyroid eye disease
  45. Interventions for involutional lower lid entropion
  46. Childhood Orbitotemporal Neurofibromatosis Masked by Congenital Glaucoma and Buphthalmos
  47. Kaposi’s Sarcoma of the Bulbar Conjunctiva in an Immunocompetent Patient
  48. Selenium and the Course of Mild Graves' Orbitopathy
  49. Entropion
  50. Management of corneal exposure & lagophthalmos
  51. Long-term follow up of autologous serum treatment for recurrent corneal erosions
  52. General Management Plan
  53. Failure of rituximab treatment in a case of severe thyroid ophthalmopathy unresponsive to steroids
  54. Management of canalicular obstructions
  55. Does the use of trypan blue during phacoemulsification affect the intraocular pressure?
  56. Orbital Exenteration for Skin Malignancies: A Single-Center Experience
  57. Surgical orbital decompression for thyroid eye disease
  58. Outcome of orbital decompression for disfiguring proptosis in patients with Graves' orbitopathy using various surgical procedures
  59. Declaración de consenso del Grupo europeo sobre la orbitopatía de Graves (EUGOGO) sobre el tratamiento de la orbitopatía de Graves (OG)
  60. O.340 Orbital exenteration for skin malignancies. A case series
  61. Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO
  62. Consensus Statement of the European Group on Graves' Orbitopathy (EUGOGO) on Management of Graves' Orbitopathy
  63. Cryopreserved amniotic membrane transplantation for the management of symptomatic bullous keratopathy
  64. ECTROPION 374.10
  65. Efficacy and Safety of Latanoprost versus Travoprost in Exfoliative Glaucoma Patients
  66. General Management Plan
  67. Clinical features of dysthyroid optic neuropathy: a European Group on Graves' Orbitopathy (EUGOGO) survey
  68. Approaches for Correcting Aponeurotic Ptosis
  69. Re: ???Clinical Features and Treatment of Graves Ophthalmopathy in Pediatric Patients???
  70. Clinical assessment of patients with Graves’ orbitopathy: the European Group on Graves’ Orbitopathy recommendations to generalists, specialists and clinical researchers
  71. A questionnaire survey on the management of Graves’ orbitopathy in Europe
  72. Reply
  73. Recent Developments in the Medical Treatment of Thyroid Eye Disease
  74. Viral Conjunctivitis Interfering with the Clinical Activity Score and Management of Thyroid Ophthalmopathy
  75. Modified Hughes Flap
  76. Twenty-four–Hour Control With Latanoprost-Timolol–Fixed Combination Therapy vs Latanoprost Therapy
  77. Outcome of External Dacryocystorhinostomy Combined With Membranectomy of a Distal Canalicular Obstruction
  78. Combination of periocular myocutaneous flaps for one-stage reconstruction of extensive defects of the eyelid
  79. Endoscopic Placement of Jones Lacrimal Tubes with the Assistance of Holmium YAG Laser
  80. Tissue plasminogen activator in the management of anterior chamber fibrin formation
  81. Nasolacrimal intubation with mitomycin C
  82. Wegener's granulomatosis of the orbit in a 5-year-old child
  83. Low-dose tissue plasminogen activator in the management of anterior chamber fibrin formation
  84. Intraobserver and interobserver reliability of the R/D score for evaluation of iris configuration by ultrasound biomicroscopy, in patients with pigment dispersion syndrome
  85. Repeatability and reproducibility of upper eyelid measurements
  86. A comparative study of two procedures for repair of involutional lower lid entropion
  87. Entropion and Ectropion